Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma.

Bridgeman, VL, Wan, E, Foo, S et al. (12 more authors) (2016) Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 15 (1). pp. 172-183. ISSN 1535-7163

Abstract

Metadata

Authors/Creators:
  • Bridgeman, VL
  • Wan, E
  • Foo, S
  • Nathan, MR
  • Welti, JC
  • Frentzas, S
  • Vermeulen, PB
  • Preece, N
  • Springer, CJ
  • Powles, T
  • Nathan, PD
  • Larkin, J
  • Gore, M
  • Vasudev, NS
  • Reynolds, AR
Copyright, Publisher and Additional Information: © 2015 American Association for Cancer Research. This is an author produced version of a paper published in Molecular Cancer Therapeutics. Uploaded in accordance with the publisher's self-archiving policy.
Dates:
  • Published: 1 January 2016
  • Accepted: 17 September 2015
Institution: The University of Leeds
Depositing User: Symplectic Publications
Date Deposited: 01 Feb 2016 10:44
Last Modified: 11 Dec 2016 12:11
Published Version: http://dx.doi.org/10.1158/1535-7163.mct-15-0170
Status: Published
Publisher: American Association for Cancer Research
Identification Number: https://doi.org/10.1158/1535-7163.mct-15-0170
Related URLs:

Share / Export

Statistics